EU warns of possible birth defect link to GSK's HIV drug
May 18, 2018 at 10:46 AM EDT
LONDON, May 18 (Reuters) - Europe's medicines regulator said it was assessing evidence that GlaxoSmithKline's successful HIV drug dolutegravir might be linked to birth defects, adding it should not be prescribed to women seeking to become pregnant.
